12.17
-1.06%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hualan Biological Engineering
Its shares trade on Shenzhen under the ticker 002007.SZ. It has been listed since 25 June 2004. In the fiscal year to 31 December 2025, it reported revenue of CN¥4.58bn and net income of CN¥940.4m. At that date it held total assets of CN¥15.26bn and shareholders' equity of CN¥11.50bn.
Hualan Biological Engineering, Inc. engages in the research, development, production, and sale of blood products, vaccines, and genetically engineered products. The company is headquartered in Xinxiang, Henan. The company went IPO on 2004-06-25. The company also produces vaccine products and biological engineering products. The firm's main products include human albumins, human immunoglobulin for intravenous injection, human immunoglobulin, human coagulation factors, human rabies immunoglobulin, human tetanus immunoglobulin and influenza vaccines, among others. The firm mainly operates its businesses in domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Jun 2004
- Employees
- 3,243
- Website
- hualanbio.com ↗
Leadership
Pay as last reported
- Mr. Kang AnChairman of the Board, since 2022CN¥1.4m
- Mr. Junmin XieChief Financial Officer, Secretary of the BoardCN¥640,000
- Ms. Bei FanGeneral Manager, DirectorCN¥1.1m
- Mr. Baoxian ZhangDeputy General Manager, DirectorCN¥910,000
- Mr. Zhengyue ChenDeputy General ManagerCN¥550,000
- Ms. Jun LiuDeputy General Manager, Chief Sales OfficerCN¥410,000
- Mr. Xiaowei MaExecutive Deputy General ManagerCN¥910,000
- Ms. Wenqi AnDirector, since 2018CN¥320,000
- Ms. Wenyu AnDirector
- Ms. Ruowen PanDirector, since 2022CN¥730,000
- Ms. Wanli LiuIndependent DirectorCN¥100,000
- Mr. Zhiguo SuIndependent DirectorCN¥100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 51
- Social
- 77
- Governance
- 73
- Women in the workforce
- 48.6%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hualan Biological Engineering employs 3243 employees in the Health Care sector.
- The company produces human albumins and immunoglobulins for domestic markets.
- Hualan's biotechnology focus includes influenza vaccines and blood products.
Weaknesses
- Hualan's business is limited to domestic markets in China.
- The company's IPO was in 2004, indicating limited recent market expansion.
- Hualan's product range focuses on blood products without diversification.
Opportunities
- Expanding into international markets for blood products and vaccines.
- Increasing demand for influenza vaccines in China's domestic market.
- Growing biotechnology sector in China supports Hualan's research and development.
Threats
- Competition from domestic biotechnology firms in China.
- Regulatory changes in China's Health Care sector could impact operations.
- Dependence on domestic market may limit growth potential.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.